Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 1/20 | 0.66 |
| ▸ | CAPN1 | P07384 | 2/20 | 0.66 |
| ▸ | CTSL | P07711 | 6/20 | 0.63 |
| ▸ | CTSK | P43235 | 6/20 | 0.60 |
| ▸ | HTRA1 | Q92743 | 1/20 | 0.59 |
| ▸ | CTSB | P07858 | 2/20 | 0.58 |
| ▸ | CTSS | P25774 | 3/20 | 0.57 |
| ▸ | REN | P00797 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL931659 | 0.91 | CAPN1 (0.69) | CAPN1CTSLCTSKHTRA1CTSB | |
| SCHEMBL31705215 | 0.91 | CAPN1 (0.74) | PTPN1CAPN1CTSLCTSKHTRA1 | |
| SCHEMBL1661924 | 0.91 | CTSL (0.71) | CAPN1CTSLCTSKCTSBCTSS | |
| SCHEMBL1663171 | 0.91 | CTSL (0.71) | CAPN1CTSLCTSKCTSBCTSS | |
| SCHEMBL6370513 | 0.89 | CTSL (0.63) | CAPN1CTSLCTSKCTSBCTSS | |
| SCHEMBL6276287 | 0.89 | CAPN1 (0.72) | CAPN1CTSLCTSKHTRA1CTSB | |
| SCHEMBL6482122 | 0.89 | CAPN1 (0.72) | CAPN1CTSLCTSKHTRA1CTSB | |
| SCHEMBL14148469 | 0.89 | CAPN1 (0.72) | CAPN1CTSLCTSKHTRA1CTSB | |
| SCHEMBL3383041 | 0.88 | CTSK (0.72) | CAPN1CTSLCTSKCTSBCTSS | |
| SCHEMBL608854 | 0.88 | CTSK (0.72) | CAPN1CTSLCTSKCTSBCTSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11021513-B2 | Peptidomimetics for the treatment of norovirus infection | EMORY UNIVERSITY (US) | 2021-06-01 | — | — | US | disclosed |
| US-20200071354-A1 | PEPTIDOMIMETICS FOR THE TREATMENT OF NOROVIRUS INFECTION | EMORY UNIVERSITY (US) | 2020-03-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11021513-B2 | Peptidomimetics for the treatment of norovirus infection | VIP, HAVCR2, NGLY1 | PTPN1 820/4885CAPN1 404/4885CTSL 280/4885 |
| US-20200071354-A1 | PEPTIDOMIMETICS FOR THE TREATMENT OF NOROVIRUS INFECTION | VIP, HAVCR2, NGLY1 | PTPN1 820/4885CAPN1 404/4885CTSL 280/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.